After two years of significant growth in non-user fee funds, House appropriators offer FDA a more modest increase for FY 2021.
House appropriators called for another increase in non-user fee funding for the US Food and Drug Administration in fiscal year 2021, but not as lavish as the previous two fiscal years, suggesting a flatter budget may be coming.
The agency would receive $3.2bn in non-user fee dollars, also known as budget authority, in the FY 2021 Agriculture, Rural...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
